Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 8/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | CA2 | P00918 | 4/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | ABAT | P80404 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13224653 | 0.83 | LMNA (0.45) | LMNAKMT2AGAAALDH1A1MAPT | |
| SCHEMBL21554140 | 0.82 | LMNA (0.42) | LMNAKMT2AGAAALDH1A1MAPT | |
| SCHEMBL17325863 | 0.80 | ALDH1A1 (0.41) | LMNAKMT2AGAAALDH1A1CA2 | |
| SCHEMBL438288 | 0.79 | OPRM1 (0.42) | LMNAKMT2AALDH1A1CA2CA9 | |
| SCHEMBL20079622 | 0.79 | ALDH1A1 (0.41) | LMNAKMT2AALDH1A1CA2CA9 | |
| SCHEMBL20079589 | 0.79 | ALDH1A1 (0.40) | LMNAKMT2AALDH1A1CA2CA1 | |
| SCHEMBL2538468 | 0.79 | KMT2A (0.43) | KMT2ACA2CA9CA1MEN1 | |
| SCHEMBL7170464 | 0.79 | KMT2A (0.43) | KMT2ACA2CA9CA1MEN1 | |
| SCHEMBL23298428 | 0.77 | CA1 (0.42) | CA2CA9CA1CA12 | |
| SCHEMBL17922627 | 0.77 | CA1 (0.39) | KMT2ACA2CA9CA1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5367 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5273743-A | A compound made up of three different Fab'-like fragments linked by a bis- or trissuccinimidyl moiety; retention of antigen binding acitivity | HYBRITECH INCORPORATED (US) | 1993-12-28 | — | — | US | claimed |
| EP-0453082-A1 | Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent | HYBRITECH INCORPORATED (US) | 1991-10-23 | — | — | EP | claimed |
| CN-122094980-A | Bispecific antibody fusion molecules targeting CD180 and CD3 and methods of use thereof | — | 2026-05-26 | — | — | CN | disclosed |
| EP-4731677-A2 | ENGINEERED BISPECIFIC MOLECULES AND METHODS OF USE | Cantai Therapeutics Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12583922-B2 | Bispecific antibodies targeting CD47 and PD-L1 and methods of use thereof | NOVIMMUNE SA (CH) | 2026-03-24 | — | — | US | disclosed |
| US-20260078425-A1 | METHODS OF PROTEIN PRODUCTION | GENENTECH, INC. (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4706769-A2 | ANTI-CD47 ANTIBODIES AND METHODS OF USE THEREOF | NovImmune SA (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20260061068-A1 | COMPOSITIONS AND METHODS RELATED TO ANTI-CD19 ANTIBODY DRUG CONJUGATES | LIGACHEM BIOSCIENCES INC (KR) | 2026-03-05 | — | — | US | disclosed |
| US-12559566-B2 | CD37-binding molecules immunoconjugates thereof | DEBIOPHARM INTERNATIONAL, S.A. (CH) | 2026-02-24 | — | — | US | disclosed |
| US-20260049135-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES | GENENTECH INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-12534465-B2 | 5H-pyrrolo[3,2-d]pyrimidine-2,4-diamino compounds and antibody conjugates thereof | SUTRO BIOPHARMA, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-5112951-A | Elution from sulfonated solid support | HYBRITECH INCORPORATED (US) | 1992-05-12 | — | — | US | disclosed |
| US-5091542-A | Trivalent coupling agents for linking fab fragments to form bifunctional and trifunctional antibody-like compounds | HYBRITECH INCORPORATED (US) | 1992-02-25 | — | — | US | disclosed |
| EP-0453082-A1 | Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent | HYBRITECH INCORPORATED (US) | 1991-10-23 | — | — | EP | disclosed |
| EP-0446071-A2 | Tris-maleimido compounds as intermediates in trifunctional antibody synthesis | HYBRITECH INCORPORATED (US) | 1991-09-11 | — | — | EP | disclosed |
| EP-0415557-A2 | Separation of anti-metal chelate antibodies | HYBRITECH INCORPORATED (US) | 1991-03-06 | — | — | EP | disclosed |
| EP-0369566-A2 | Bifunctional chimeric antibodies | HYBRITECH INCORPORATED (US) | 1990-05-23 | — | — | EP | disclosed |
| EP-0369567-A2 | Chimeric antibodies directed against metal chelates | HYBRITECH INCORPORATED (US) | 1990-05-23 | — | — | EP | disclosed |
| EP-0327365-A2 | Improvements in or relating to modified haptens useful as imaging and therapeutic agents | HYBRITECH INCORPORATED (US) | 1989-08-09 | — | — | EP | disclosed |
| EP-0315456-A2 | Polysaccharide-modified immunoglobulins having reduced immunogenic potential or improved pharmacokinetics | HYBRITECH INCORPORATED (US) | 1989-05-10 | — | — | EP | disclosed |